Lakefront Biotherapeutics (GLPGF) Cost of Revenue (2021 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Cost of Revenue for 6 consecutive years, with $10.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 100.07% year-over-year to $10.6 million in Q2 2026; TTM through Jun 2026 was $34.6 billion, a 85696.99% increase from a year earlier, with the FY2025 full-year figure at $33.6 billion, up 88934.97% from the prior year.
• Cost of Revenue was $10.6 million for Q2 2026 at Lakefront Biotherapeutics, up from $5.6 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $34.6 billion in Q4 2025 and troughed at -$577211.7 in Q2 2024.
• A 5-year average of $1.9 billion and a median of $4.9 million in 2023 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue slumped 112.54% in 2024 and surged 1903438.57% in 2025, its largest moves.
• Over 5 years, Cost of Revenue stood at $4.2 million in 2022, then jumped by 358.41% to $19.4 million in 2023, then slumped by 90.62% to $1.8 million in 2024, then surged by 1903438.57% to $34.6 billion in 2025, then slumped by 99.97% to $10.6 million in 2026.
• The last three Cost of Revenue figures came in at $10.6 million (Q2 2026), $5.6 million (Q1 2026), and $34.6 billion (Q4 2025), per Business Quant data.